Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
Methi Wathikthinnakon, Piriya Luangwattananun, Nunghathai Sawasdee, Chutipa Chiawpanit, Vannajan Sanghiran Lee, Piyarat Nimmanpipug, Yingmanee Tragoolpua, Siriphorn Rotarayanont, Thanich Sangsuwannukul, Nattaporn Phanthaphol, Yupanun Wutti‑in, Chalermchai Somboonpatarakun
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCholangiocarcinoma and Gallbladder Cancer Studies · RNA Interference and Gene Delivery · CAR-T cell therapy research
Correction to: Scientific Reports 10.1038/s41598-022-09964-6, published online 13 April 2022
In the original version of this Article, the approval number for the PBMC isolation was incorrect.
As a result, In the Methods section, under the subheading ‘Peripheral blood mononuclear cell (PBMC) isolation and culture’
“PBMC isolation was performed according to the guidelines of both the Declaration of Helsinki and the Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (approval no. Si 517/2018).”
now reads:
“PBMC isolation was performed according to the guidelines of both the Declaration of Helsinki and the Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (approval no. Si 517/2016).”
The original Article has been corrected.